A Phase I Study Evaluating the Pharmacokinetic Profile of a Novel, Proprietary, Nano-formulated, Lower-Dose Oral Indomethacin

References

• . Haanpaa ML, Backonja MM, Bennett MI, . Assessment of neuropathic pain in primary care. Am J Med. 2009;122( 10 suppl):S13–S21
   PubMed Web of Science ®Google Scholar
• . Mantyselka P, Kumpusalo E, Ahonen R, . Pain as a reason to visit the doctor: a study in Finnish primary health care. Pain. 2001;89(2–3): 175–180
   PubMed Web of Science ®Google Scholar
• . McCarberg B. Treatment of mild-to-moderate acute pain: what can we do to improve the standard of care? Am J Ther. 2008;15( suppl 10):S5–S6
   PubMed Web of Science ®Google Scholar
• . Hart FD, Boardman PL. Indomethacin: a new non-steroid anti-inflammatory agent. Br Med J. 1963;2(5363):965–970
   PubMedGoogle Scholar
• . Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician. 1999;59(4):925–934
   PubMed Web of Science ®Google Scholar
• . Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician. 1999;59(7):1799–1806, 1810
   PubMed Web of Science ®Google Scholar
• . Gotzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials. 1989;10(1):31–56
   PubMedGoogle Scholar
• . Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007;5(1):19–34
   PubMedGoogle Scholar
• . Gluszko P, Bielinska A. Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors? Pol Arch Med Wewn. 2009; 119(4):231–235
   PubMed Web of Science ®Google Scholar
• . Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56(3):387–437
   PubMed Web of Science ®Google Scholar
• . Graham DJ, Campen D, Hui R, . Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475–481
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Public health advisory. FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm. 2005. Accessed on September 15, 2011
   Google Scholar
• . Food and Drug Administration. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108361.htm 2004. Accessed on September 15, 2011
   Google Scholar
• . García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343(8900):769–772
   PubMed Web of Science ®Google Scholar
• . Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective—1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl. 1998;51:8–16
   PubMedGoogle Scholar
• . Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Res Ther. 2005;7( suppl 4):S14–S22
   PubMed Web of Science ®Google Scholar
• . Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320–326
   PubMed Web of Science ®Google Scholar
• . Riera—Guardia N, Castellsague J, Calingaert B, . The SOS Project: nonsteroidal anti-inflammatory drugs and upper gastrointenstinal complications. Meta-analysis of epidemiological studies. In: International Conference on Pharmacoepidemiology. 2010. Brighton, UK; 2010
   Google Scholar
• . Bueno H, Bardaji A, Patrignani P, Martin—Merino E, Garcia—Rodriguez LA. Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol. 2010;105(8):1102–1106
   PubMedGoogle Scholar
• . Fosbol EL, Folke F, Jacobsen S, . Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes. 2010;3(4):395–405
   PubMed Web of Science ®Google Scholar
• . Fosbol EL, Gislason GH, Jacobsen S, . Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190–197
   PubMed Web of Science ®Google Scholar
• . Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52(20):1628–1636
   PubMed Web of Science ®Google Scholar
• . Gislason GH, Jacobsen S, Rasmussen JN, . Risk of death or rein—farction associated with the use of selective cyclooxygenase–2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906–2913
   PubMed Web of Science ®Google Scholar
• . Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sørensen HT. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011;343:d3450
   PubMed Web of Science ®Google Scholar
• . Gooch K, Culleton BF, Manns BJ, . NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(3):280e1–e7
   Google Scholar
• . Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol. 2000;151(5):488–496
   PubMed Web of Science ®Google Scholar
• . Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee IM, Yang CY. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2010;19(7):745–751
   PubMedGoogle Scholar
• . US Department of Health and Human Services FDA, Center for Drug Evaluation and Research. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies; 2002
   Google Scholar
• . Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med. 1999;107(6A):3S–8S; discussion 8S–10S
   PubMedGoogle Scholar
• . Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340(24):1888–1899
   PubMed Web of Science ®Google Scholar
• . Boardman PL, Hart FD. Side-effects of indomethacin. Ann Rheum Dis. 1967;26(2):127–132
   PubMedGoogle Scholar
• . Biskupiak JE, Brixner DI, Howard K, Oderda GM. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother. 2006;20(3):7–14
   PubMedGoogle Scholar
• . Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5(2):137–142
   PubMedGoogle Scholar
• . Garcia Rodriguez LA, Hernandez—Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Am J Epidemiol. 2004;159(1):23–31
   PubMed Web of Science ®Google Scholar
• . Griffn MR, Piper JM, Daugherty JR, . Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114(4):257–263
   PubMedGoogle Scholar
• . Laporte JR, Ibanez L, Vidal X, . Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411–420
   PubMed Web of Science ®Google Scholar
• . Lewis SC, Langman MJ, Laporte JR, . Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320–326
   PubMed Web of Science ®Google Scholar
• . Mellemkjaer L, Blot WJ, Sørensen HT, . Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol. 2002;53(2):173–181
   PubMedGoogle Scholar
• . Wang J, Donnan PT, MacDonald TM. An approximate Bayesian risk-analysis for the gastro-intestinal safety of ibuprofen. Pharmacoepidemiol Drug Saf. 2002;11(8):695–701
   PubMedGoogle Scholar
• . Bombardier C, Laine L, Reicin A, ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520–1528
   PubMed Web of Science ®Google Scholar
• . Bresalier RS, Sandler RS, Quan H, ; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–1102
   PubMed Web of Science ®Google Scholar
• . Graham DJ, Campen D, Hui R, . Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475–481
   PubMed Web of Science ®Google Scholar
• . McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-Inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Medicine. 2011;8(9):e1001098
   PubMed Web of Science ®Google Scholar
• . Nussmeier NA, Whelton AA, Brown MT, . Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081–1091
   PubMed Web of Science ®Google Scholar
• . Ott E, Nussmeier NA, Duke PC, . Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125(6):1481–1492
   PubMed Web of Science ®Google Scholar
• . Solomon SD, McMurray JJ, Pfeffer MA, . Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–1080
   PubMed Web of Science ®Google Scholar
• . FlectorPatch [package insert]. Bristol, TN: King Pharmaceuticals, Inc. February 2011
   Google Scholar
• . VoltarenGel [package insert]. Basel, Switzerland: Novartis; October 2009
   Google Scholar